BAF312 + Placebo

Phase 2Terminated

0 views this week 0 watching💤 Quiet

Interest: 27/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Polymyositis

Conditions

Polymyositis, Dermatomyositis

Trial Timeline

Jun 15, 2010 → Jun 13, 2012

NCT ID

NCT01148810

About BAF312 + Placebo

BAF312 + Placebo is a phase 2 stage product being developed by Novartis for Polymyositis. The current trial status is terminated. This product is registered under clinical trial identifier NCT01148810. Target conditions include Polymyositis, Dermatomyositis.

What happened to similar drugs?

0 of 1 similar drugs in Polymyositis were approved

Approved (0) Terminated (0) Active (1)

🔄Abatacept subcutaneous + PlaceboBristol Myers SquibbPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (4)

NCT ID	Phase	Status	Start	Completion	Indication
NCT02029274	Phase 2	Terminated	Aug 25, 2013	Feb 17, 2016	Active Dermatomyositis
NCT01665144	Phase 3	Completed	Dec 20, 2012	Mar 31, 2023	Secondary Progressive Multiple Sclerosis
NCT01148810	Phase 2	Terminated	Jun 15, 2010	Jun 13, 2012	Polymyositis
NCT00879658	Phase 2	Completed	Mar 30, 2009	May 4, 2011	Relapsing-remitting Multiple Sclerosis

Competing Products

6 competing products in Polymyositis

See all competitors

Product	Company	Stage	Hype Score
tacrolimus	Astellas Pharma	Pre-clinical	26
Placebo + BAF312	Novartis	Phase 2	27
MEDI7734 + Placebo	Amgen	Phase 1	29
Abatacept subcutaneous + Placebo	Bristol Myers Squibb	Phase 3	40
KZR-616	Kezar Life Sciences	Phase 2	25
KZR-616 + Placebo	Kezar Life Sciences	Phase 2	25